- £242.42m
- £217.42m
- £48.70m
Brief: Niox Group Announces All AGM Resolutions Passed
Brief: Niox Group Reports Trading For Year In Line With Expectations
AGM Statement
Grant of SAYE options
Director/PDMR Shareholding
Notice of 2026 Annual General Meeting
Exercise of Options, Director Dealing and TVR
Grant of Options
Director/PDMR Shareholding and Total Voting Rights
Holding(s) in Company
UK's Niox 2025 revenue rises 17% on demand for pharma-sponsored clinical trials
Final Results
Holding(s) in Company
UK's Niox revenue up 17%, ahead of market expectations
Full Year Trading Update
Block Listing Application
Director/PDMR Shareholding
Holding(s) in Company
Block Listing Application